Overview of Runxin Biotech at CPHI China 2026 Runxin Biotech will exhibit at CPHI China 2026 in Shanghai, presenting pharmaceutical, cosmetic, and food grades of sodium hyaluronate, chondroitin sulfate, and glucosamine. The portfolio includes biofermentation-derived chondroitin sulfate and multiple glucosamine forms. At the booth, the team will discuss customized molecular weight specifications, regulatory documentation support, stability data, and flexible MOQs for various applications. The event reflects ongoing quality advancements in China’s pharmaceutical ingredient sector.

Overview of Runxin Biotech at Vitafoods Europe 2026 Runxin Biotech participated in Vitafoods Europe 2026 in Barcelona, showcasing pharmaceutical-grade sodium hyaluronate, chondroitin sulfate, and glucosamine. European buyers emphasized clean label credentials, regulatory documentation, batch-to-batch consistency, and supply chain traceability. Emerging application areas included GLP-1 companion nutrition, women’s health, and healthy aging. The event reinforced demand for technical partnership and pre-assembled regulatory support for EU market access.

Sodium hyaluronate powder serves as a highly effective topical lubricant that alleviates dry eye symptoms by stabilizing the tear film and accelerating corneal epithelial healing, yet its structural density and macromolecular weight can physically obstruct the trabecular meshwork when introduced int

Hyaluronic acid (HA) is a naturally occurring substance in the body that plays a key role in maintaining joint health, skin hydration, and wound healing. In recent years, hyaluronic acid injections have gained popularity as a treatment for joint pain, particularly for individuals suffering from oste